Biocon Biologics

As part of the deal, Serum Life Sciences, a unit of SII, will pick up a 3.9 per cent stake in Oxford Biomedica

Dr Arun Chandavarkar, Managing Director, Biocon Biologics talks to Akanki Sharma about his role and vision for the company, while…

While patients will be increasingly prescribed Viatris/Biocon’s Semglee over Sanofi’s Lantus due to its competitive pricing,…

Interchangeable designation allows substitution at the pharmacy counter for Lantus across the US to help increase access to…

Biocon Biologics to manufacture and commercialise a broadly neutralising antibody for India and select emerging markets

Abevmy 100 and 400 mg is approved for the treatment of metastatic colorectal carcinoma, metastatic breast cancer, non small-cell…

Biocon Biologics, has a footprint in the majority of the top 20 emerging markets and will be a meaningful contributor to the…

Biocon Biologics announced that Shreehas Tambe has been promoted to the position of Deputy Chief Executive Officer of Biocon…

Bevacizumab inhibits the formation of tumor vasculature, thereby inhibiting tumor growth

The partnership coincides with the start of the centenary celebrations of the discovery of insulin